Invivyd Inc (IVVD)
2.40
-0.05
(-2.04%)
USD |
NASDAQ |
May 17, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
Invivyd Net Income (Quarterly): -43.50M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -43.50M |
| December 31, 2023 | -73.65M |
| September 30, 2023 | -39.44M |
| June 30, 2023 | -50.23M |
| March 31, 2023 | -35.32M |
| December 31, 2022 | -44.57M |
| September 30, 2022 | -45.09M |
| Date | Value |
|---|---|
| June 30, 2022 | -50.99M |
| March 31, 2022 | -100.67M |
| December 31, 2021 | -83.04M |
| September 30, 2021 | -60.38M |
| June 30, 2021 | -44.67M |
| March 31, 2021 | -38.70M |
| September 30, 2020 | -48.01M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-100.67M
Minimum
Mar 2022
-35.32M
Maximum
Mar 2023
-54.16M
Average
-46.55M
Median
Net Income (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | -4.146M |
| Viking Therapeutics Inc | -27.36M |
| Stoke Therapeutics Inc | -26.37M |
| 180 Life Sciences Corp | -1.227M |
| MAIA Biotechnology Inc | -8.068M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 46.09M |
| EPS Diluted (Quarterly) | -0.38 |
| Enterprise Value | 96.97M |
| Earnings Yield | -77.92% |